Umirolimus

Umirolimus is a drug used in drug-eluting stents to prevent restenosis. It is a semi-synthetic derivative of sirolimus and works by inhibiting cell proliferation.

Mechanism of action

Umirolimus inhibits the mammalian target of rapamycin (mTOR) pathway, which is a key regulator of cell growth and proliferation. By blocking this pathway, umirolimus prevents the proliferation of smooth muscle cells that can lead to restenosis.

Use in drug-eluting stents

Umirolimus is used in the BioMatrix drug-eluting stent system. This system uses a biodegradable polymer that releases umirolimus into the blood vessel wall over a period of several months. The slow release of the drug helps to prevent restenosis without causing the problems associated with permanent polymers.

Clinical trials

Several clinical trials have demonstrated the effectiveness of umirolimus in preventing restenosis. The LEADERS trial, for example, found that the BioMatrix stent was superior to a bare-metal stent in terms of preventing restenosis and major adverse cardiac events.

Side effects

As with all drugs, umirolimus can cause side effects. These can include pain, inflammation, and infection. However, these side effects are generally rare and the benefits of preventing restenosis typically outweigh the risks.

See also

• Sirolimus
• Drug-eluting stent
• Restenosis
• Mammalian target of rapamycin

Umirolimus Resources
Latest articles Most recent articles Ongoing trials	Wikipedia